rs7951 — C3

C3 rs7951 — A Synonymous Variant That Silently Reduces Complement Levels

The complement system is one of the immune system's oldest defense mechanisms — a cascade of proteins that coat pathogens, signal immune cells, and clear cellular debris and immune complexes from the circulation. Complement C3¹¹ Complement C3
The central protein of all three complement activation pathways — classical, lectin, and alternative — through which every activation route converges is the most abundant complement protein in blood, and its serum concentration is under measurable genetic control. The rs7951 variant in the C3 gene is a synonymous coding change (c.4311C>T, p.Ala1437=) that does not alter the amino acid sequence, yet carriers of the minor A allele consistently show lower serum C3 levels — demonstrating that silent mutations can have functional consequences through effects on mRNA stability, splicing, or translational efficiency. This lower complement tone has clinical implications for autoimmune disease susceptibility, particularly systemic lupus erythematosus, where complement deficiency is both a cause and a consequence of disease activity.

The Mechanism

Although rs7951 causes no amino acid change, synonymous variants in coding sequences can affect protein production through several mechanisms: altered mRNA secondary structure²² mRNA secondary structure
Synonymous substitutions change the local folding energy of the mRNA transcript, which can affect ribosomal elongation speed and co-translational protein folding, changes in codon usage bias affecting translation kinetics, and disruption of exonic splicing enhancers that regulate mRNA processing. The rs7951 variant lies within exon 41 of C3 (coding position 4311, chromosome 19 minus strand), and the T allele in the coding sequence corresponds to the A allele on the genomic plus strand. The Miyagawa et al. 2008 study³³ Miyagawa et al. 2008 study
509 Japanese SLE cases and 964 controls genotyped at rs7951 and rs2230201 in C3 demonstrated directly that serum C3 levels were significantly lower in A-allele carriers compared to non-carriers (P=0.0018), confirming functional impact despite the synonymous annotation. The rs7951 A allele is part of a 3'-end haplotype block in C3 that has been replicated across independent population studies as regulating C3 protein expression.

The physiological consequence of reduced C3 levels is impaired complement-mediated immune complex clearance⁴⁴ complement-mediated immune complex clearance
Soluble immune complexes (antigen-antibody aggregates) accumulate in tissues when complement-mediated solubilization and erythrocyte CR1 transport are impaired, triggering local inflammation in kidneys, skin, and joints. In lupus, this becomes a self-amplifying process: autoantibodies form immune complexes, complement is consumed trying to clear them, low C3 levels impair clearance further, and deposited complexes activate inflammatory cascades in the kidneys (lupus nephritis), skin, and joints.

The Evidence

The primary evidence for rs7951 comes from a Japanese case-control study by Miyagawa et al.⁵⁵ Miyagawa et al.
509 SLE patients and 964 healthy controls, two C3 SNPs genotyped: rs7951 and rs2230201 (2008), which screened 53 candidate genes in 316 SNPs across Japanese SLE patients and controls. The rs7951 A allele frequency was 0.110 in SLE patients versus 0.081 in controls (OR=1.40, 95% CI 1.05–1.86, P=0.016). Critically, among 87 patients with available serum data, mean serum C3 was significantly lower in A-allele carriers (P=0.0018) — establishing a direct genotype-to-phenotype link. A companion SNP at the locus, rs2230201, also showed association (OR=1.19, P=0.038), consistent with a shared haplotype effect.

A UK SLE family study by Rhodes et al. 2009⁶⁶ Rhodes et al. 2009
1,371 individuals from 393 UK white European SLE families; Bayesian variance components model for serum C3 heritability replicated the finding that C3 3'-end variants regulate serum C3 levels, estimating 39.6% heritability for circulating C3 concentration. The study identified rs344555 (in the same 3'-haplotype block as rs7951) as most strongly associated with serum C3 levels (P=0.007), and a separate variant, rs3745568, as most associated with SLE disease status (P=0.0046). The converging finding across Japanese and European populations is that genetic variation at the 3' end of C3 modulates both protein level and disease risk — though the specific causal SNP has not been definitively resolved.

Practical Implications

Reduced complement C3 activity affects two domains: infection defense and autoimmune disease susceptibility. For most carriers of one A allele (AG genotype), the functional impact is modest — circulating C3 levels remain in the low-normal range, and most carriers never develop clinical disease. For homozygous AA carriers, the reduction is more substantial, but frank C3 deficiency (very rare, typically <10 mg/dL) would require additional rare variants. The key practical relevance is autoimmune surveillance: reduced complement impairs clearance of apoptotic cells and immune complexes, raising the likelihood that autoantibody-mediated inflammation will establish and persist.

Interactions

rs7951 lies in the same C3 3'-haplotype block as rs344555 and rs3745568, both of which have been independently associated with serum C3 levels or SLE in UK populations. These three variants may tag the same causal functional element, or may have partially independent effects within the block; fine-mapping studies have not definitively resolved this. The C3F/S functional variant rs2230199 (p.Arg102Gly) is a separate, independent missense variant in C3 associated with AMD and IgA nephropathy progression — its effects involve altered complement activation kinetics rather than reduced C3 expression levels. Individuals carrying both rs7951-A (lower C3 levels) and rs2230199-C3F (altered activation efficiency) may have compounded complement dysregulation, though this combination has not been directly studied.